Equities

OSE Immunotherapeutics SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

OSE Immunotherapeutics SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)4.25
  • Today's Change-0.06 / -1.39%
  • Shares traded140.51k
  • 1 Year change-36.38%
  • Beta0.4655
Data delayed at least 15 minutes, as of Mar 02 2026 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

OSE Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company, engaged in clinical stage biotechnological sector. It develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The Company's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. It provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

  • Revenue in EUR (TTM)2.22m
  • Net income in EUR-34.84m
  • Incorporated2004
  • Employees68.00
  • Location
    OSE Immunotherapeutics SA22, boulevard Benoni GoullinNANTES 44200FranceFRA
  • Phone+33 228291010
  • Fax+33 141219107
  • Websitehttps://ose-immuno.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gensight Biologics SA194.00k-15.12m19.55m13.00------100.77-0.1293-0.12930.0016-0.2450.0174--10.7816,166.67-135.38-81.19---203.71-----7,793.81-868.76--------18.3916.4746.60---57.94--
Valbiotis SA472.00k-11.12m24.31m44.00--2.07--51.51-0.6994-0.69940.02970.49670.02061.574.8910,727.27-48.58-33.12-61.97-47.09-603.8119.74-2,354.87-464.772.93-74.380.3129---96.3013.97-36.06---2.02--
Novacyt SA21.80m-31.68m28.39m234.00--0.6084--1.30-0.4489-0.49160.30910.66080.23542.345.2793,175.38-34.205.59-39.097.2963.3566.74-145.329.834.59-7.230.2114--84.8211.35-60.50--55.60--
genOway SA20.95m1.29m31.00m148.0016.411.157.671.480.14870.14872.422.120.5940.87973.69146,514.103.652.104.722.9194.9194.806.143.762.21--0.4407--10.0418.4616.79--15.88--
Fermentalg SA12.78m-11.54m39.98m63.00--1.41--3.13-0.1242-0.12420.13530.31560.24727.913.29199,734.40-17.09-18.10-21.17-20.5920.9425.51-69.14-147.661.83--0.2368--183.3243.528.99---4.91--
Theranexus SA0.00-2.94m46.49m10.00---------0.3641-0.36410.00-0.19230.00----0.00-66.82-44.47-148.89-50.85-----------37.712.90------74.15---56.53--
Eurofins Cerep SA40.46m7.15m80.20m207.0011.211.128.381.981,418.431,418.438,027.2414,234.140.49551.614.75195,445.808.7613.1210.2315.9085.6780.0217.6820.226.53--0.0046---8.205.46-6.3410.36----
Ose Immunotherapeutics SA2.22m-34.84m96.82m68.00--1.91--43.63-1.59-1.590.10092.260.0181--0.482134,671.88-28.42-7.66-33.45-9.27-----1,569.85-26.10----0.4331--3,646.5226.31262.78---25.52--
Abionyx Pharma SA4.33m-4.60m120.74m51.00--21.49--27.91-0.1317-0.13170.12380.15820.303317.397.1684,823.53-32.25-26.53-43.11-38.3117.7815.59-106.31-131.061.35--0.4281---1.92---24.53------
Adocia SA10.35m-9.71m131.37m77.00------12.69-0.5622-0.56220.6343-0.03380.4068--2.55134,428.60-38.16-47.62-184.08-104.50-----93.83-331.171.12-14.581.06--333.4934.1855.95---35.29--
Maat Pharma SA3.92m-31.13m135.53m60.00--14.01--34.56-2.15-2.150.2700.51410.078611.220.578565,366.67-62.39-41.51-90.20-51.8761.68---793.83-976.992.21-29.530.6346--44.34---46.59--42.53--
Innate Pharma SA6.00m-46.05m137.24m181.00--26.23--22.87-0.5497-0.54970.07140.05580.0491--15.8133,149.17-37.68-13.19-52.10-17.1749.5291.15-767.52-88.46----0.8401---75.68-28.80-553.51---64.08--
Sensorion SA0.00-28.09m186.93m68.00--1.92-----0.0931-0.09310.000.18950.00----0.00-32.12-34.53-38.36-43.50------------0.0265-------17.72--98.90--
Data as of Mar 02 2026. Currency figures normalised to OSE Immunotherapeutics SA's reporting currency: Euro EUR

Institutional shareholders

2.72%Per cent of shares held by top holders
HolderShares% Held
abrdn, Inc.as of 31 Jan 2026275.42k1.23%
Saint Olive Gestion SNCas of 30 Jun 2025160.00k0.71%
Mandarine Gestion SAas of 30 Jun 2025122.58k0.55%
Dimensional Fund Advisors LPas of 05 Feb 202631.25k0.14%
CPR Asset Management SAas of 31 Dec 202511.45k0.05%
Chaussier Gestion SAas of 31 Dec 20256.00k0.03%
Gestys SAas of 30 Jan 20263.00k0.01%
Friedland Gestion SASas of 25 Jul 20251.90k0.01%
Adepa Asset Management SAas of 30 Jun 20250.000.00%
1832 Asset Management LPas of 30 Jun 20250.000.00%
More ▼
Data from 30 Jun 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.